The recent approval of the therapeutic drugs ivosidenib (IDH1) and enasidenib (IDH2) by the Food and Drug Administration (FDA) has been an important advance in the treatment of patients with AML patients containing IDH mutations [10]. This evidence concerns the gene IDH2 and acute myeloid leukemia.